Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease

Skyba P., Ukropec J., Pobeha P., Ukropcova B., Joppa P., Kurdiova T.

Prospective Study on Type 2 Diabetes, published in Mediators Inflamm (2010) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Mediators Inflamm (2010)
Reported sample size
—
Source database
Europe PMC
PMID
21197447
PMCID
PMC3010654
DOI
10.1155/2010/173498
Citations
18

Abstract (original English)

Potential links between metabolic derangements and adipose tissue (AT) inflammation in patients with chronic obstructive pulmonary disease (COPD) are unexplored. We investigated AT expressions of interleukin (IL)-6, tumor necrosis factor (TNF)-α, CD68 (macrophage cell surface receptor), caspase-3, and Bax, and their relationships to the metabolic phenotype in nine cachectic, 12 normal-weight, 12 overweight, and 11 obese patients with COPD (age 62.3 ± 7.2 years). With increasing body mass index, increases in AT expressions of IL-6, TNF-α, and CD68 were observed (P < .001; P = .005; P < .001, resp.), in association with reduced insulin sensitivity (P < .001). No differences were observed between cachectic and normal-weight patients in AT expressions of inflammatory or proapoptotic markers. Adipose tissue CD68 and TNF-α expressions predicted insulin sensitivity independently of known confounders (P = .005; P = .025; R(2) = 0.840). Our results suggest that AT inflammation in obese COPD patients relates to insulin resistance. Cachectic patients remain insulin sensitive, with no AT upregulation of inflammatory or proapoptotic markers.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueHumansPulmonary Disease, Chronic ObstructivePanniculitisInsulin ResistanceObesityInflammationCachexiaTumor Necrosis Factor-alphaReceptors, Tumor Necrosis Factor, Type I

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research